Multiple endocrine neoplasia types 1 and 2: Phenotype, genotype, diagnosis, and therapeutic plan with special reference to children and adolescents

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 2, 1997, Pages 91-99

  Hoff, Ana O ^a   Gagel, Robert F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002309372     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199704000-00004     Document Type: Article

References (97)

1. Warmer P: Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954, 16:363-371.
2. Calender A, Giraud S, Cougard P, Chanson P, Lenoir G, Mural A, Hamon P, Proye C: Multiple endocrine neoplasia type 1 in France: clinical and genetic studies. J Intern Med 1995, 238:263-268. Large-scale application of DNA markers closely linked to the MEN 1 gene made it possible to determine gene carrier status with near certainty in 150 families.
3. Padberg B, Schroder S, Capella C, Frilling A, Kloppel G, Heitz PU: Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch 1995, 426:541-548.
4. Skogseid B, Rastad J, Oberg K: Multiple endocrine neoplasia type 1: clinical features and screening. Endocrinol Metab Clin North Am 1994, 23:1-18.
5. Skogseid B, Eriksson B, Lundqvist G, Lorelius LE, Rastad J, Wide L, Akerstrom G, Oberg K: Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991, 73:281-287.
6. Skogseid B, Oberg K: Experience with multiple endocrine neoplasia type 1 screening. J Intern Med 1995, 238:255-261. Prospective biochemical screening is an effective approach to early identification of MEN 1 gene carriers. The authors discuss their experience with biochemical screening and their current recommendations.
7. Mallette LE: Management of hyperparathyroidism in the multiple endocrine neoplasia syndromes and other familial endocrinopathies. Endocrinol Metab Clin North Am 1994, 23:19-36.
8. Thompson NW: The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995, 238:269-260.
9. Gagel RF: Multiple endocrine neoplasia. In Williams Textbook of Endocrinology, edn 9. Edited by Wilson JD, Foster DW, Larsen PR, Kronenberg H. Philadelphia: WB Saunders; 1997: in press.
10. Teh BT, Grimmond S, Shepherd J, Larsson C, Hayward N: Multiple endocrine neoplasia type I: clinical syndrome to molecular genetics. Aust N Z J Surg 1995, 65:708-713.
11. Skogseid B, Grama D, Rastad J, Eriksson B, Lindgren PG, Ahlstrom H, Lorelius LE, Wilander E, Akerstrom G, Oberg K: Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1. J Intern Med 1995, 238:281-288. The efficiency of preoperative pancreatic imaging studies was evaluated in 12 MEN 1 patients in whom pancreatic disease had been diagnosed on the basis of biochemical screening. Portal venous sampling was the most sensitive preoperative localization method and intraoperative ultrasonography showed the best overall sensitivity.
12. Vassilopoulou-Sellin R, Ajani J: Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am 1994, 23:53-65.
13. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Hacki WH, Stamm B, Heitz PU, Kloppel G: Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990, 322:723-727.
14. O'Riordain DS, O'Brien T, van Heerden JA, Service FJ, Grant CS: Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994, 18:488-493; discussion 493-494.
15. McCutcheon IE: Management of individual tumor syndromes: pituitary neoplasia. Endocrinol Metab Clin North Am 1994, 23:37-51.
16. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM: Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996, 81:2642-2646. A prospective assessment of the prevalence of nonfunctional pituitary adenomas and the utility of the α-subunit in a large MEN 1 kindred (165 family members). Eighteen percent had pituitary disease; prolactinomas were the most frequent tumors and 24% were nonfunctional tumors. The α-subunit was elevated in 29% of pituitary tumors (prolactinomas and nonfunctional tumors) and was also elevated in patients with pancreatic disease only.
17. Scheithauer BW, Laws ERJ, Kovacs K, Horvath E, Randall RV, Carney JA: Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987, 4:205-211.
18. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM: Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. J Clin Endocrinol Metab 1996, 81:1841-1845. The different inheritance patterns of prolactinomas were evaluated in a large Tasmanian MEN 1 kindred. Two of four branches of the family show an autosomal dominant pattern of inheritance. The authors suggest an independent genetic risk factor, in addition to a MEN 1 gene defect.
19. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM: Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred. Am J Med 1996, 100:544-547.
20. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995, 80:3395-3405. A good review of the pathogenesis and management of growth hormone-producing tumors.
21. Aron DC, Tyrrell JB, Wilson CB: Pituitary tumors: current concepts in diagnosis and management. West J Med 1995, 162:340-352.
22. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P: Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992, 74:577-584.
23. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332:85-87.
24. Lagercrantz J, Larsson C, Grimmond S, Skogseid B, Gobl A, Friedman E, Carson E, Phelan C, Oberg K, Nordenskjold M, et al.: Candidate genes for multiple endocrine neoplasia type 1. J Intern Med 1995, 238:245-248.
25. Teh BT, Cardinal J, Shepherd J, Hayward NK, Weber G, Cameron D, Larsson C: Genetic mapping of the multiple endocrine neoplasia type 1 locus at 11q13. J Intern Med 1995, 238:249-253.
26. Grimmond S, Weber G, Larsson C, Walters M, Teh B, Shepherd J, Nordenskjold M, Hayward N: Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. Hum Genet 1995, 95:455-458.
27. Weber G, Friedman E, Grimmond S, Hayward NK, Phelan C, Skogseid B, Gobl A, Zedenius J, Sandelin K, Teh BT: The phospholipase C beta 3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Hum Mol Genet 1994, 3:1775-1781.
28. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM, O'Riordan JL: Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989, 321:218-224.
29. Bystrom C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, Oberg K, Werner S, Nordenskjold M: Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 1990, 87:1968-1972.
30. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S: Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993, 105:579-582.
31. Thakker RV, Pook MA, Wooding C, Boscaro M, Scanarini M, Clayton RN: Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J Clin Invest 1993, 91:2815-2821.
32. Skogseid B, Rastad J, Gobl A, Larsson C, Backlin K, Juhlin C, Akerstrom G, Oberg K: Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 1995, 118:1077-1082. Forty-three MEN 1 patients were prospectively screened for adrenal lesions by means of biochemical and imaging studies. Seventeen (40%) had adrenal enlargement; three of these patients had adrenocortical cancer.
33. Teh BT, Hayward NK, Walters MK, Shepherd JJ, Wilkinson S, Nordenskjold M, Larsson C: Genetic studies of thymic carcinoids in multiple endocrine neoplasia type 1 [letter]. J Med Genet 1994, 31:261-262.
34. de Montpreville VT, Macchiarini P, Dulmet E: Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg 1996, 111:134-141.
35. Burgess JR, Harte RA, Tucker P, Parameswaran V, Davies P, Greenaway TM, Shepherd JJ: Adrenal lesions in a large kindred with multiple endocrine neoplasia type I. Arch Surg 1996, 131:699-702. A retrospective review of 33 patients from the Tasmanian MEN 1 kindred revealed 12 patients (36%) with adrenal lesions. These lesions were nonfunctional, were not malignant, and were associated with pancreatic lesions in all cases.
36. Thakker RV: The role of molecular genetics in screening for multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 1994, 23:117-135.
37. Smith CM, Wells SA, Gerhard DS: Mapping eight new polymorphisms in 11q13 in the vicinity of multiple endocrine neoplasia type 1: identification of a new distal recombinant Hum Genet 1995, 96:377-387.
38. Larsson C, Calender A, Grimmond S, Giraud S, Hayward NK, Teh B, Farnebo F: Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1. J Intern Med 1995, 238:239-244. Until the causative MEN 1 gene is identified, genetic testing relies on linkage analysis, an indirect but accurate approach to identifying gene carriers. A panel of Southern blot and polymerase chain reaction-based markers is discussed. PYGM plus one informative flanking marker on each side of the MEN 1 locus provides accuracy of nearly 100%.
39. Mole SE, Mulligan LM, Healey CS, Ponder BA, Tunnacliffe A: Localization of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2. Hum Mol Genet 1993, 2:247-252.
40. Lairmore TC, Dou S, Howe JR, Chi D, Carlson K, Veile R, Mishra SK, Wells SA Jr, Donis-Keller H: A 1.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loci (RET, D10S94, and D10S102) closely linked to the MEN2A locus. Proc Natl Acad Sci U S A 1993, 90:492-496.
41. Gardner E, Papi L, Easton DF, Cummings T, Jackson CE, Kaplan M, Love DR, Mole SE, Moore JK, Mulligan LM: Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 1993, 2:241-246.
42. Goodfellow PJ, Wells SA Jr: RET gene and its implications for cancer. J Natl Cancer Inst 1995, 87:1515-1523.
43. Gagel RF: Putting the bits and pieces of the RET proto-oncogene puzzle together. Bone 1995, 17:13S-16S.
44. Donis-Keller H: The RET proto-oncogene and cancer. J Intern Med 1995, 238:319-325.
45. Raue F, Frank-Raue K, Grauer A: Multiple endocrine neoplasia type 2: clinical features and screening. Endocrinol Metab Clin North Am 1994, 23:137-156.
46. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA: Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989, 111:802-806.
47. Bugalho MJ, Limbert E, Sobrinho LG, Clode AL, Soares J, Nunes JF, Pereira MC, Santos MA: A kindred with multiple endocrine neoplasia type 2A associated with pruritic skin lesions. Cancer 1992, 70:2664-2667.
48. Cote GJ, Wohllk N, Evans D, Goepfert H, Gagel RF: RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocnnol Metab 1995, 9:609-630.
49. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S: C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 1996, 81:2731-2733. A novel MEN 2A-Hirschsprung's disease kindred is described. Analysis of c-ret protooncogene revealed a heterozygous C618R mutation in exon 10.
50. Hazard JB, Hawk WA, Crile G Jr: Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 1959, 19:152-161.
51. Telander RL, Moir CR: Medullary thyroid carcinoma in children. Semin Pediatr Surg 1994, 3:188-193.
52. Dralle H, Scheumann GF, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berner M, Niederle B, Vasen HFA: The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med 1995, 238:357-361. This is a retrospective, multicenter study of 139 patients with hereditary MTC. Systematic (compartment-oriented microdissection technique) as opposed to selective dissection, in which only macroscopically involved lymph nodes are removed, improved the biochemical cure rate in patients with nodal disease (no distal metastasis) who had small primary tumors (< 1 cm).
53. O'Riordain DS, O'Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA: Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994, 116:1017-1023.
54. Evans DB, Lee JE, Merrell RC, Hickey RC: Adrenal medullary disease in multiple endocrine neoplasia type 2: appropriate management. Endocrinol Metab Clin North Am 1994, 23:167-176.
55. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G: Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993, 329:1531-1538.
56. Howe JR, Norton JA, Wells SA Jr: Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993, 114:1070-1077.
57. Modigliani E, Vasen H, Raue K, Dralle H, Frilling A, Gheri R, Brandi M, Limbert E, Niederle B, Forgas L, et al.: Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 1995, 238:363-367. A retrospective review of 300 MEN 2 patients with pheochromocytoma. Sixty-eight percent had bilateral disease and only 4% had malignant pheochromocytoma. Sixty-four of the deaths in this group were related to pheochromocytoma. A prolonged, systematic biochemical follow-up is recommended.
58. Gagel RF, Tashjian AH Jr, Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A: an 18-year experience. N Engl J Med 1988, 318:478-484.
59. Telenius-Berg M, Ponder MA, Berg B, Ponder BAJ, Werner S: Quality of life after bilateral adrenalectomy in MEN 2. Henry Ford Hosp Med J 1989, 37:160-163.
60. Lairmore TC, Ball DW, Baylin SB, Wells SA Jr: Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993, 217:595-601; discussion 601-603.
61. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC: Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996, 120:1064-1071. Cortical-sparing adrenalectomy was performed in 15 patients with bilateral pheochromocytoma. Ninety-three percent had a normal, postoperative Cortisol level and did not require steroid replacement.
62. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B: Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995, 238:369-373.
63. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA: Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995, 118:936-942. A review of phenotype and treatment of 21 MEN 2B patients from the Mayo Clinic. MTC was the most common cause of death; 50% of patients presented with lymph node metastases at the time of surgery. These authors recommend total thyroidectomy and central nodal dissection with modified radical neck dissection when there is evidence of gross or microscopic lateral nodal disease.
64. Wohllk N, Cote GJ, Evans D, Goepfert H, Ordonez N, Gagel RF: Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia. Endocrinol Metab Clin North Am 1996, 25:1-25. This review discusses c-ret protooncogene mutations, methods of mutation analysis, and clinical management of gene carriers, with special focus on MTC and prophylactic thyroidectomy.
65. Skinner MA, De Benedetti MK, Moley JF, Norton JA, Wells SA Jr: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996, 31:177-181; discussion 181-182. This study compared MEN 2 children who underwent thyroidectomy for MTC during childhood, prior to the availability of genetic screening, with children undergoing thyroidectomy on the basis of genetic screening. After a mean follow-up of 9.3 years in the first group, five of 24 patients had recurrent disease. There was no recurrence in the second group after a mean follow-up of 1.3 years. In this latter group all of the patients had evidence of C-cell disease but only four had positive pentagastrin test results.
66. Gagel RF, Cote GJ, Martins Bugalho MJG, Boyd AE, Cummings T, Goepfert H, Evans DB, Cangir A, Khorana S, Schultz PN: Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995, 238:333-341. Presents genotype-phenotype correlations in 28 MEN 2A kindreds. All affected individuals had mutations involving exons 10 or 11. Mutations at codon 634 were the most common. Four children underwent thyroidectomy on the basis of genetic testing; three (3.5 to 12 years of age) had bilateral C-cell hyperplasia and one (11 years of age) had microscopic MTC.
67. Mole SE, Mulligan LM, Healey CS, Ponder BAJ, Tunnacliffe A: Localization of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2. Hum Mol Genet 1993, 2:247-252.
68. Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985, 42:581-588.
69. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L: Germline mutations of the RET protooncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 1993, 363:458-460.
70. Donis-Keller H, Shenshen D, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856.
71. Kwok JBJ, Gardner E, Warner JP, Ponder BAJ, Mulligan LM: Structural analysis of the human Ret proto-oncogene using exon trapping. Oncogene 1993, 8:2575-2582.
72. Lin LF, Doherty DH, Lile JD, Bektesh S, Colline F: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
73. Trupp M, Arenas E, Falnzilber M, Nilsson AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U: Functional receptor for QDNF encoded by the c-ret proto-oncogene. Nature 1996, 381:785-788.
74. Durbec P, Marcos-Gutierrez CV, Kilkenny C, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sarlola H, Pachnis V: GDNF signalling through the ret receptor tyrosine kinase. Nature 1996, 381:789-793.
75. Sanchez M, Silos-Santiago I, Frisen J, He B, Lira S, Barbacid M: Newborn mice lacking GDNF display renal agenesis and absence of enteric neurons, but no deficits in midbrain dopaminergic neurons. Nature 1996, 382:70-73.
76. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A: Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382:76-79.
77. Pichel JG, Shen L, Sheng HZ, Granholm A-C, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, Sariola H, Westphal H: Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996, 382:73-76. The role of GDNF during development was assessed by disruption of the GDNF gene. GDNF knockout mice had kidney dysgenesis and defective enteric innervation.
78. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994, 367:380-383.
79. Mulligan LM, Ponder BA: Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995, 80:1989-1995. A review of c-ret protooncogene mutations with correlation to phenotype. The clinical application of genetic data is discussed.
80. Neumann HP, Eng C, Mulligan LM, Glavac D, Zauner I, Ponder BA, Crossey PA, Maher ER, Brauch H: Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 1995, 274:1149-1151.
81. Gagel RF, Cote GJ: Ret protooncogene mutations in multiple endocrine neoplasia type 2. In Principles of Bone Biology, edn 1. Edited by Bilezikian JP, Raisz LG, Rodan GA. San Diego: Academic Press; 1996:799-807.
82. Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, for the German Medullary Thyroid Carcinoma Study Group: Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996, 81:1780-1783. Presents genotype-phenotype correlations in 94 MEN 2 families. Eighty-one percent of MEN 2A families had a codon 634 mutation; of these 37% were cysteine-to-arginine mutations. Any mutation at codon 634 was more likely to be associated with pheochromocytoma; a cysteine-to-arginine mutation did not predict for parathyroid disease. Kindreds with familial MTC had mutations in exon 10 (52%) or 11 (44%). Of eight MEN 2B patients, seven had a de novo mutation at codon 918, and in one no mutation was found.
83. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Van Amstel HKP, Lips CJM, Nishisho I, Takai SI, et al.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996, 276:1575-1579. The International RET Mutation Consortium correlated mutations with phenotype in 477 families. Eighty-five percent of MEN 2A patients had a codon 634 mutation; 95% of MEN 2B patients had a mutation at codon 918. The majority of patients with familial MTC had mutations in exons 10 and 11; only three of 34 families had mutations in exon 13 (codon 768) or 14 (codon 804).
84. Eng C: The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996, 335:943-951. A review focusing on c-ret protooncogene mutations in MEN 2A, familial MTC, MTC, MEN 2A-Hirschsprung's disease, and MEN 2B, with correlation to phenotype.
85. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10:509-513.
86. Rossel M, Schuffenecker I, Schlumberger M, Bonnardel C, Modigliani E, Gardet P, Navarro J, Luo Y, Romeo G, Lenoir G, Billaud M: Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Gener 1995, 95:403-406.
87. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiiore PP: Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995, 267:381-383. Transfection of mutant RET alleles in NIH 3T3 cells caused constitutive activation of the RET kinase and transformation, establishing the oncogenic potential of mutant RET.
88. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA: Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996, 56:2167-2170. Subpopulations of MTC patients (several metastases in a single individual or different regions within a primary MTC) were analyzed for somatic c-ret protooncogene mutations. A mutation at codon 918 was found in at least one tumor cell subpopulation in 80% of sporadic tumors. One of two MEN 2A MTCs involved this mutation in addition to the germline ret mutation. The authors suggest that the codon 918 mutation may arise during tumor progression or that MTC is of polyclonal origin.
89. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, De Benedetti MK, Dilley WG, Moley JF: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994, 220:237-250.
90. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW: Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995, 118:257-263; discussion 263-264.
91. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828-835.
92. Gagel RF, Cote GC: Decision making in multiple endocrine neoplasia type 2. Adv Endocrinol Metab 1994, 5:1-23.
93. Ledger GA, Khosla S, Lindor NM, Thibodeau SN, Gharib H: Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995, 122:118-124. Ledger et al. from the Mayo Clinic focus on the clinical use of genetic information and on the failure of pentagastrin testing in identifying C-cell hyperplasia or MTC in some patients. They recommend prophylactic thyroidectomy in patients with MEN 2A or 2B on the basis of genetic screening.
94. Frilling A: Preventive total thyroidectomy in children with MEN-2A syndrome [letter]. Chirurg 1994, 65:408.
95. Frilling A, Hoppner W, Eng C, Mulligan L, Raue F, Broelsch CE: Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. J Mol Med 1995, 73:229-233. Genetic testing is the method of choice for identification of MEN 2 gene carriers, and prophylactic thyroidectomy is recommended at age 5 years in MEN 2A patients.
96. Iitia A, Mikola M, Gregersen N, Hurskamen P, Lovgren T: Detection of a point mutation using short oligonucleotide probes in allele-specific hybridization. Biotechniques 1994, 17:566-573.
97. Mischiati C, Fiorentino D, Feriotto G, Gambari R: Use of an automated laboratory workstation for isolation of genomic DNA suitable for PCR and allele-specific hybridization. Biotechniques 1993, 15:146-151.